Switching from Transdermal to Oral Estrogen Therapy

Dose Conversion Guidelines

A 1:20 dose conversion ratio is recommended when switching from transdermal to oral estrogen therapy, with a 100 mcg/day transdermal patch being approximately equivalent to 2 mg oral micronized estradiol daily, according to the American College of Obstetricians and Gynecologists 1
The standard conversion is straightforward: 50 mcg/day transdermal patch = 1 mg oral estradiol daily, 100 mcg/day transdermal patch = 2 mg oral estradiol daily, and 200 mcg/day transdermal patch = 4 mg oral estradiol daily, as suggested by the North American Menopause Society 1

Transdermal administration carries significantly lower cardiovascular and thrombotic risks compared to oral estrogen therapy, and switching from transdermal to oral estrogen should be strongly reconsidered in most patients, as recommended by the American Heart Association 1
Transdermal estradiol has a neutral effect on venous thromboembolism risk (OR 0.9), whereas oral estradiol significantly increases VTE risk (OR 4.2), representing a nearly 5-fold difference in thrombotic risk between routes, according to the American College of Cardiology 1

In patients with radiation-induced premature ovarian insufficiency, transdermal 17β-estradiol is strongly preferred over oral formulations due to superior uterine development outcomes, as recommended by the American Society for Reproductive Medicine 2, 1

If switching is deemed necessary despite the risks, the equivalent oral dose should be calculated using the 1:20 conversion ratio, and the transdermal patch should be discontinued and oral estradiol begun on the same day to avoid estrogen withdrawal symptoms, as suggested by the Endocrine Society 1
The same progestin regimen should be maintained for endometrial protection, with 200 mg oral micronized progesterone for 12-14 days every 28 days in women with an intact uterus, as recommended by the American College of Obstetricians and Gynecologists 1, 3